Evidence map›Paper›PMID 34423286›Full record

ArticleFrontiers in big data2021

A Multi-Study Model-Based Evaluation of the Sequence of Imaging and Clinical Biomarker Changes in Huntington's Disease.

Peter A Wijeratne, Eileanoir B Johnson, Sarah Gregory, Nellie Georgiou-Karistianis, Jane S Paulsen, Rachael I Scahill, Sarah J Tabrizi, Daniel C Alexander

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in big data, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Peter A WijeratneCentre for Medical Image Computing, Department of Computer Science, University College London, London, United Kingdom.
Eileanoir B JohnsonHuntington's Disease Research Centre, Department of Neurodegenerative Disease, University College London, Queen Square Institute of Neurology, London, United Kingdom.
Sarah GregoryHuntington's Disease Research Centre, Department of Neurodegenerative Disease, University College London, Queen Square Institute of Neurology, London, United Kingdom.
Nellie Georgiou-KaristianisMonash Institute of Cognitive and Clinical Neurosciences, School of Psychological Sciences, Faculty of Nursing, Medicine, and Health Sciences, Monash University Clayton Campus, Clayton, VIC, Australia.
Jane S PaulsenDepartments of Neurology and Psychiatry, Carver College of Medicine, University of Iowa, Iowa City, IA, United States.
Rachael I ScahillHuntington's Disease Research Centre, Department of Neurodegenerative Disease, University College London, Queen Square Institute of Neurology, London, United Kingdom.
Sarah J TabriziHuntington's Disease Research Centre, Department of Neurodegenerative Disease, University College London, Queen Square Institute of Neurology, London, United Kingdom.
Daniel C AlexanderCentre for Medical Image Computing, Department of Computer Science, University College London, London, United Kingdom.
University College London · GBHuntington's Disease Association · GBMonash University · AUNational Hospital for Neurology and Neurosurgery · GBUniversity of Iowa · US

Funding

Preparing for preventive clinical trials in Huntington's diseaseU01NS105509 · NINDS · UNIVERSITY OF WISCONSIN-MADISON · PI PAULSEN, JANE S · 2020 to 2025
$2.5M
Statistical disease modeling and clinimetrics to prepare for preventive trials in huntington diseaseU01NS103475 · NINDS · UNIVERSITY OF WISCONSIN-MADISON · PI PAULSEN, JANE S · 2020 to 2022
$1.7M
Medical Research Council MR/T027770/1NINDS NIH HHS U01 NS103475NINDS NIH HHS U01 NS105509
6 · The paper itself

Abstract

Understanding the order and progression of change in biomarkers of neurodegeneration is essential to detect the effects of pharmacological interventions on these biomarkers. In Huntington's disease (HD), motor, cognitive and MRI biomarkers are currently used in clinical trials of drug efficacy. Here for the first time we use directly compare data from three large observational studies of HD (total

Indexed as

biomarkersclinical stagingdisease progression modelhuntington’s diseasemulti-study investigation

Identifiers

PMID34423286
PMCPMC8374237
OpenAlexW3190128877

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.